Euclid, a Boston MA-based AI-backed cardiovascular disease diagnosis software, raised $27 million in a Series B round.
The company’s series B was headed by an unnamed strategic investor. Additional funders included Biovision Ventures, and ongoing investors, MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
Euclid will commercialize its AI-based heart disease diagnosis software to market after garnering $27 million in a Series B round.
Company: Elucid Bioimaging Inc.
Raised: $27.0 M
Round: Series B
Funding Month: June 2022
Lead Investors Undisclosed
Additional Investors: Biovision Ventures, MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
Company Website: https://elucid.com/
Software Category: AI-backed Diagnosis software
About the Company: Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe.